Literature DB >> 16893486

Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them.

K M Roy1, S J Hutchinson, S Wadd, A Taylor, S O Cameron, S Burns, P Molyneaux, P G McIntyre, D J Goldberg.   

Abstract

It is estimated that of 50,000 persons in Scotland (1% of the county's population), infected with the hepatitis C virus (HCV), around 90% injected drugs. This paper reviews data on the prevalence and incidence of HCV, and the methods used to generate such information, among injecting drug users (IDUs), in Scotland. The prevalence estimate for HCV among IDUs in Scotland as a whole (44% in 2000), is comparable with those observed in many European countries. Incidence rates ranged from 11.9 to 28.4/100 person-years. The data have shaped policy to prevent infection among IDUs and have informed predictions of the number of HCV-infected IDUs who will likely progress to, and require treatment and care for, severe HCV-related liver disease. Although harm reduction interventions, in particular needle and syringe exchanges and methadone maintenance therapy, reduced the transmission of HCV among IDUs during the early to mid-1990s, incidence in many parts of the country remains high. The prevention of HCV among IDUs continues to be one of Scotland's major public health challenges.

Entities:  

Mesh:

Year:  2006        PMID: 16893486      PMCID: PMC2870592          DOI: 10.1017/S0950268806007035

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  25 in total

1.  Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends among young injectors halt in the late 1990s.

Authors:  S J Hutchinson; P G McIntyre; P Molyneaux; S Cameron; S Burns; A Taylor; D J Goldberg
Journal:  Epidemiol Infect       Date:  2002-06       Impact factor: 2.451

2.  Over a decade of syringe exchange: results from 1997 UK survey.

Authors:  James Parsons; Matthew Hickman; Paul J Turnbull; Tim McSweeney; Gerry V Stimson; Ali Judd; Kay Roberts
Journal:  Addiction       Date:  2002-07       Impact factor: 6.526

3.  HIV and hepatitis C among injecting drug users.

Authors:  R A Coutinho
Journal:  BMJ       Date:  1998-08-15

4.  Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates.

Authors:  H G Watson; C A Ludlam; S Rebus; L Q Zhang; J F Peutherer; P Simmonds
Journal:  Br J Haematol       Date:  1992-04       Impact factor: 6.998

5.  Hepatitis virus infection and liver disease in injecting drug users who died suddenly.

Authors:  E A McCruden; K J Hillan; I C McKay; M T Cassidy; J C Clark
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

6.  Pilot study to estimate survivors to 1995 of 1983-1984 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983-1984.

Authors:  S M Gore; R P Brettle; S M Burns; S C Lewis
Journal:  J Infect       Date:  1998-09       Impact factor: 6.072

7.  Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study.

Authors:  J K Champion; A Taylor; S Hutchinson; S Cameron; J McMenamin; A Mitchell; D Goldberg
Journal:  Am J Epidemiol       Date:  2004-03-01       Impact factor: 4.897

8.  Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis.

Authors:  S J Hutchinson; D J Goldberg; M King; S O Cameron; L E Shaw; A Brown; J MacKenzie; K Wilson; L MacDonald
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.

Authors:  D Goldberg; S Cameron; J McMenamin
Journal:  Commun Dis Public Health       Date:  1998-06

10.  Establishment of a database of diagnosed HCV-infected persons in Scotland.

Authors:  L Shaw; A Taylor; K M Roy; S O Cameron; S Burns; P Molyneaux; P McIntyre; G Codere; D Goldberg
Journal:  Commun Dis Public Health       Date:  2003-12
View more
  14 in total

1.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

2.  Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach.

Authors:  J M Tait; Brian P Stephens; Paul G McIntyre; Morgan Evans; John F Dillon
Journal:  Frontline Gastroenterol       Date:  2013-05-11

3.  HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.

Authors:  M Florencia Etcheverry; Paula J Lum; Jennifer L Evans; Emilia Sanchez; Elisa de Lazzari; Eva Mendez-Arancibia; Ernesto Sierra; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

4.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

5.  Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection.

Authors:  D Hegazy; P Thurairajah; M Metzner; A Houldsworth; S Shaw; E Kaminski; A G Demaine; M E Cramp
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

6.  Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population.

Authors:  A J Sutton; S A McDonald; N Palmateer; A Taylor; S J Hutchinson
Journal:  Epidemiol Infect       Date:  2012-03-30       Impact factor: 4.434

Review 7.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

8.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

9.  A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.

Authors:  Marie Jauffret-Roustide; Yann Le Strat; Elisabeth Couturier; Damien Thierry; Marc Rondy; Martine Quaglia; Nicolas Razafandratsima; Julien Emmanuelli; Gaelle Guibert; Francis Barin; Jean-Claude Desenclos
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090

10.  Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow.

Authors:  Avril Taylor; Sharon J Hutchinson; Gail Gilchrist; Sheila Cameron; Susan Carr; David J Goldberg
Journal:  Harm Reduct J       Date:  2008-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.